Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 308

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 308
---
 November 30, 2025, and shall bear interest at 8% per annum
until maturity commencing as of September 1, 2024. Furthermore, upon the occurrence of a Qualified IPO, the Bridge Loan lenders,
shall be granted warrants to purchase such number of Ordinary Shares equal to 140,000 Ordinary Shares following the consummation of
this offering.

Between December 2023
and January 2024, we entered into the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000
from certain lenders, including certain related parties. In October 2024, we amended the 2024 Loan Agreements pursuant to which the
2024 Loan Agreements have been extended until August 31, 2025, and during September 2025, the 2024 Loan Agreements were further
extended to November 30, 2025, and shall bear interest at 8% per annum until maturity commencing as of September 1, 2024.
Furthermore, upon the occurrence of a Qualified IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase such
number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share
equal to 61,538 Ordinary Shares following the consummation of this offering.

On December 1, 2024,
we entered into the December 2024 Loan Agreement with our Chief Executive Officer, according to which accrued payroll salary owed to
him in the aggregate amount of $117,000 plus VAT was converted into a loan. The loan amount bears interest at an 8% annual rate, and
is due upon the earlier of the consummation of this offering or March 31, 2025. In addition, upon maturity, the Company will pay to
our Chief Executive Officer an aggregate risk premium equal to 30% of the loan amount (or approximately $35,100 plus VAT). If a
registration statement for an initial public offering is made effective no later than March 31, 2025, then the maturity date will be
extended to June 30, 2025. In addition, pursuant to the December 2024 Loan Agreement, upon the consummation of this offering the
Company will issue warrants, or the CEO Loan Warrants, exercisable for a period of three years from the date of the issuance, to
purchase such number of Ordinary Shares equal to two